Inovio Pharmaceuticals, Inc. announced its financial results for Q4 and full year 2025, highlighting the acceptance of its BLA for INO-3107 by the FDA and promising clinical data. The company aims to optimize resources for a potential approval by October 30, 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.